BioStem Technologies Inc. (OTC:BSEM) Stock In Focus After Recent News

If you are currently looking into the regenerative medicine space, then you could consider taking a closer look at BioStem Technologies Inc. (OTC:BSEM). It is a regenerative medicine company involved in the manufacturing, development, and commercialization of biologics derived from the placenta for providing new-age wound care.

On Tuesday, the company hit the newswires after it announced that it had appointed a new member to its board of directors in the form of Patrick Daly. In the news release provided by the company yesterday, BioStem Technologies noted that Daly was an award-winning executive and boasted a strong and successful record in the domains of fundraising, operations, sales, partnership building, marketing, and strategy.

The Chief Executive Officer of the company, Jason Matuszewski, spoke about the appointment. He noted that everyone at the company was highly excited about the latest appointment. He added that the management team at BioStem Technologies also looked forward to leveraging the considerable industry-level relationships and experience possessed by Daly in the medical technology and biomaterials spaces. It was also noted that Daly was an advisor at Pappas Capital, a private equity firm involved with the life sciences industry.

He had recently served as the Global Vice President of Commercial Solutions and eventually the Global Vice President of Medtech Data Delivery at IQVIA Holdings. During his time at that firm, Daly was responsible for being in charge of the worldwide strategies for the MedTech Commercial Solutions unit.

In the past, he had also been the President and Chief Executive Officer of Cohera Medical, a commercial stage life science company involved in the development of biomaterials for surgical adhesives. The company had eventually been acquired by KKR, the investment behemoth. It remains to be seen if the BioStem Technologies stock gets any attention from investors today.